Table 3.

Overview of extraparenchymal patients

Patient number	Age (years)	Gender	Years followed at NIH	Duration of etanercept (days)	Followed up post-etanercept (year)	Etanercept dose (mg/week)	Use of cysticidal medication(s) with etanercept	Disease type	Reason for etanercept	Medication regimens	Outcome
2	35	M	4.1	31	0.0	50	Yes	SUBNCC	Failed corticosteroid taper, added immunosuppression and sparing	Corticosteroids + methotrexate to corticosteroids + methotrexate + 50 mg etanercept	Short-term improvement. lost to follow-up at 31 days
4	41	F	0.4	NA	NA	50	Yes	Spinal SUBNCC	Failed corticosteroid taper + anakinra, added immunosuppression and corticosteroid sparing	Corticosteroids + anakinra to corticosteroids + 50 mg etanercept + anakinra	Tapered from 29 mg prednisone to 0.5 mg with mild improvement of symptoms due to spinal disease. Continues on etanercept
6	41	F	5.0	41	4.9	25	Yes	SUBNCC	Added immuosuppression, corticosteroid sparing	Corticosteroids + methotrexate + 25 mg etanrecept to corticosteroids	Improved short term but on taper developed neurological symptoms controlled on high-dose corticosteroids alone
7	51	M	1.6	380	0.3	50	Yes	SUBNCC	Corticosteroid replacement for corticosteroid psychosis	50 mg etanercept	Dramatic clinical improvement
8	57	M	0.7	NA	NA	50	Yes	SUBNCC, spinal	Added immunosuppression, corticosteroid replacement, and sparing	Corticosteroids to corticosteroids + 50 etanercept	Still on etanercept, moderate clinical improvement of pain due to spine involvement
9	41	F	4.0	699	2.1	25,50	Yes	SUBNCC, ventricular	Failed corticosteroid taper, added immunosuppression and sparing	Corticosteroids to corticosteroids + methotrexate to corticosteroids + methotrexate + 50 mg etanercept to 50 mg etanercept	Taper successful after the dose of etanercept was increased and did well on etanercept alone
10	30	M	3.6	272	2.6	25	Yes	SUBNCC, calcification	Failed corticosteroid taper, added immunosuppression and sparing	Corticosteroids to corticosteroids + 25 mg etanercept	Taper successful after the dose of etanercept was increased and did well on etanercept alone
11	37	M	6.6	229	5.6	25	Yes	SUBNCC, calcifications	Failed corticosteroid taper + methotrexate, added immunosuppression and sparing	Corticosteroids + methotrexate to 25 mg etanrecept + corticosteroids + methotrexate + 25 mg etanercept to methotrexate + 25 mg etanercept	Taper successful and avoided worsening in avascular necrosis on corticosteroid side effects
12	26	M	8.0	461	5.6	25	Yes	SUBNCC	Failed corticosteroid taper, added immunosuppression and sparing	Corticosteroids to corticosteroids + methotrexate to corticosteroids + methotrexate + 25 mg etanercept + methotrexate to 25 mg etanercept + corticosteroids to 25 mg etanercept	Taper successful and avoided further worsening of avascular necrosis of the hip
13	41	M	4.9	350	3.2	25	Yes	SUBNCC	Added immunosuppression	Corticosteroids to 25 mg etanercept corticosteroids + methotrexate to 25 mg etanercept to methotrexate to methotrexate	Developed large vessel stroke after completing therapy, resulting in retreatment that avoided additional vascular complications
14	28	M	6.3	356	4.6	25	No	Ventricular calcifications	Added immunosuppression and corticosteroid sparing	Corticosteroids to corticosteroids + methotrexate + 25 mg etanercept to corticosteroid + 25 mg etanercept to 25 mg etanercept	Taper successful and on prolonged etanercept with loss of priventricular edema and associated symptoms
15	39	F	4.7	210	3.4	25	No	SUBNCC	Failed corticosteroid taper, added immunosuppression, and replacement	Corticosteroids + methotrexate to 25 mg etanercept + corticosteroids + methotrexate + 25 mg etanercept to methotrexate	Taper successful with improved symptoms and loss of corticosteroid side effects, although improved still has headaches and depression, but no further transient episodes of hemiparalysis

NIH = National Institutes of Health; SUBNCC = subarachnoid neurocysticercosis.